Alydia developed a non-invasive, FDA-approved medical device, the Jada® System, which is designed to reduce healthcare costs and eradicate maternal death caused by postpartum hemorrhage: excessive bleeding following delivery. In March 2021, on behalf of its planned spinoff Organon, Merck announced its plan to acquire Alydia Health for up to $240M; the acquisition was completed in June 2021.
President: Troy Davis (previously Rob Binney)
Headquarters: Menlo Park, CA
Year Founded: 2011
Year Avestria First Invested: 2018 (Fund I)
Acquired: 2021
Looking for a job opportunity at Organon? Click here.
Recent Press:
Alydia mentioned in Deloitte’s analysis of the women’s health market
Alydia mentioned in an article covering women’s health
Colby Holtshouse receives Pulse-Setting Trailblazer Award on behalf of the Jada® System
Real-world study shows that Alydia’s Jada® System is safe and highly effective
Organon calls for recognition for the repercussions of underinvesting in women’s health
De-risking and self-advocacy are keys to changing women’s health research and development
Rob Binney joins ShiraTronics Inc. as new CEO
8 health and medicine milestones from 2021
Organon’s Kevin Ali named one of Comparably’s best CEOs of 2021
Organon’s Susi Fiedler on surmounting women’s health challenges
Organon receives FDA clearance for technological updates to the Jada® System
Sharon Vosmek of Astia Angels: how making money can be an articulation of your values
Cal Poly HotHouse company started as a senior project. It just sold for $240M.
Organon completes acquisition of Alydia Health
Organon shows how women’s health can be fertile ground for investment. Here’s why.
Alydia’s Jada System named one of Fast Company’s World Changing Ideas
Alydia Health acquired for up to $240M
Alydia Health named one of Fierce Medtech’s 2020 Fierce 15
Northeast Georgia Medical Center receives life-saving technology for new moms
Treating PPH: A novel, vacuum-induced hemorrhage control device
How to learn more about Alydia at SMFM 2021
FDA clearance for Alydia’s Jada is one of Healio’s top women’s health stories of 2020
BU’s Alum Spotlight: Kathryn Wine, VP of Clinical Operations
Alydia named among industry leaders in Postpartum Hemorrhage Treatment Device Market research report
Alydia among winners of JNJ Innovation’s Maternal Health QuickFire Challenge
Jada named among Cleveland Clinic Innovation’s Top 10 medical innovations for 2021
Erica Rogers among winners of Entrepreneur Of The Year® Award in Northern California
Alydia Health announces FDA clearance and publication of pivotal study
Intrauterine Vacuum-Induced Hemorrhage-Control Device for Rapid Treatment of Postpartum Hemorrhage
The Jada System for Postpartum Hemorrhage: Interview with Rob Binney, CEO of Alydia Health
Alydia announces new funding and new leadership appointments
Alydia completes pivotal trial enrollment
Alydia appoints new board member
New device to stop postpartum bleeding could save lives
Anne Morrissey talks car accidents, career guidance, and raising $10 million
February 28, 2024: In this analysis of women’s health, called “Can Investors Help Women’s Health Break Through the Glass Ceiling?”, the authors note the investments trends in women’s health and gender-based health outcomes that have gone unaddressed due to the lack of funding supporting companies, innovations, and research. Alydia was mentioned as one of the notable exits in women’s health.
December 21, 2023: Alydia Health was mentioned in this deep dive into women’s health. This piece was published in Insider Precision Medicine, but, as the article itself notes, the concept of precision medicine can be applied not only individuals of different weights, heights, and genetics but also to individuals of different genders. Organon was mentioned as a large company that is focused exclusively on women’s health, including through its acquisition of Alydia Health in 2021. Organon even recently released the results of the RUBY study, the first real-world, observational, post-market registry review study of Alydia’s Jada® System, which reinforced Jada®’s effectiveness in helping to manage postpartum hemorrhaging. AOA Dx., a current Avestria portfolio company, was also mentioned in the article.
October 13, 2023: Colby Holtshouse received the Cardiovascular Research Foundation (CRF)’s Pulse-Setting Trailblazer Award. Awarded annually, the 2023 Pulse-Setter Awards recognize “extraordinary individuals and initiatives whose dedication to innovation is driving positive change in medicine and health care”. Colby Holtshouse was recognized for her past work developing and commercializing Alydia’s Jada® System and for her current work as Global MedTech Commercial Lead at Organon where she helps bring Jada® to mothers around the world.
February 10, 2023: This study, published in the American Journal of Obstetrics and Gynecology, shares the results of the first, large, real-world trial for Alydia’s Jada® System. Jada® was cleared for use by the FDA in 2021 after the company’s investigational study and included 107 patients. This study shows Jada®’s impact on 800 patients from October 2020 to April 2022 and shows that the device is safe and effective, treating postpartum hemorrhaging effectively for both vaginal and cesarean births and, for the majority of patients, in no more than five minutes. (Read the corresponding press release here.)
February 7, 2023: Before International Women’s Day on March 8, 2023, Organon called for the repercussions of underinvesting in women’s health. In this press release, Organon noted that, although women make up around half the population and the majority of healthcare decision-makers, only 5% of the FDA-approved prescription drugs in 2022 were for female-specific health conditions and only 1% of healthcare research and innovation is invested in women’s specific healthcare conditions besides oncology as of 2022.
December 28, 2022: Alydia was founded in 2010 and its Jada® System was approved by the FDA and the company acquired in Organon almost 11 years later. Although Alydia’s device has the potential to save the lives of thousands of new mothers by helping to stop postpartum hemorrhaging - one of the main causes of maternal mortality - the slow journey through product-building, clinical trials, and commercialization shows that women’s health innovations are still the victim of gender bias. Note: membership required for viewing.
August 26, 2022: In this article, Dr. Sandy Milligan, M.D., head of research and development at Organon, describes the challenges and opportunities facing women’s health research and development. Under 4% of all research and development funding goes to women’s health, and Dr. Milligan and Organon are addressing this discrepancy by making listening to women’s voices and addressing their healthcare needs. Organon’s portfolio of companies addressing women’s health includes not only Alydia Health but also Nexplanon and NuvaRing.
May 12, 2022: After helping Alydia commercialize its Jada® System and leading the company to and through its acquisition by Organon, Rob Binney is leaving the company to join ShiraTronics Inc. ShiraTronics is developing solutions for chronic migraine patients, and, after he officially starts his new role in July, Rob will be responsible for guiding ShiraTronics through its clinical trials and subsequent commercialization.
January 7, 2022: Alydia’s Jada® System was named one of Verywell Health’s top eight health and medicine milestones from 2021. Jada® was recognized not only for its ability to control postpartum hemorrhages quickly and effectively but also for its ease of use for physicians.
December 15, 2021: Kevin Ali of Organon was named one of Comparably’s best CEOs of 2021. The list, generated from employee data, broke down the top CEOs of large companies and of small to medium businesses based on 15 million ratings across 70,000 CEOs. Under Kevin Ali’s leadership, Organon completed its spin-off from Merck, acquired Alydia Health among others, and is establishing itself as a company that supports and advocates for women’s health.
October 19, 2021: After 25 years at Merck, Susi Fielder moved to its spin-off, Organon, as its Chief Commercial Officer. In this interview, she covers her background and how it lead to her current role, the advice she’d give to women working in and around the pharmaceutical industry, and some of Organon’s early wins, including its acquisition of Alydia Health.
October 11, 2021: Organon has received FDA clearance for updates to the Jada® System, which was developed by Alydia Health: Organon’s first acquisition. The updates include a new kit configuration with updated packaging and a streamlined design to help improve Jada®’s ease of use. Organon estimates that this version will be available to U.S customers in January 2022.
September 22, 2021: Sharon Vosmek is the CEO of Astia Angels and one of the early investors in Alydia Health. In this Forbes article, she shares that investing is about putting money behind who and what you personally believe matter - like Alydia Health’s Jada System. As she says, “Alydia Health has not only a phenomenal innovation for doctors to save lives, it is at a price point that can be used both in developed markets like the U.S. and the U.K., and emerging markets.”
July 5, 2021: This article covers the beginnings of Alydia Health, when it was still called InPress Technologies and was originated by Jessie Becker Alexander, Nathan Bair, Davis Carlin, Alex Norred as a senior project in 2011. In this article, Jessie Becker Alexander and Nathan Bair recount Alydia’s path to acquisition, including some of the connections they leveraged - including Cal Poly’s Center for Innovation and Entrepreneurship (CIE) HotHouse Accelerator program - their humanitarian mission, and their fundraising path. To date, Alydia has the largest acquisition price of any Cal Poly CIE-affiliated companies.
June 16, 2021: Organon announced that its acquisition of Alydia Health was officially completed. The acquisition, which was announced in March 2021, is part of Organon’s strategy not only to expand its medical device portfolio but also to focus on addressing women’s unmet health needs, such as postpartum hemorrhaging. Together, Organon and Alydia are working to bring Alydia’s Jada System to moms around the world.
June 15, 2021: While Big Pharma has generally stayed away from women’s health, Organon is leaning into that space. Its portfolio, which already included contraceptive and fertility products such as Nexplanon, also includes Alydia Health: an acquisition that allows Organon to establish its presence in both the medical device field and the maternal health sector. As of May 2021, Organon predicts $6.1 billion to $6.4 billion in revenue for 2021.
May 4, 2021: Alydia’s Jada System is one of the finalists for Fast Company’s “World Changing” ideas for healthcare. The finalists, as well as the honorable mentions, were chosen based on their ability to save lives, extend longevity, or increase access to care.
April 27, 2021: Paul Praino has joined Alydia as the new Vice President of Sales. Paul Praino, an industry veteran of almost 15 years, has been part of medical device sales teams at companies such as Access Closure, Acclarent and Intersect ENT. Most recently, he was the Global Vice President, Sales at Intersect ENT. He will be leading Alydia’s growing U.S commercial organization.
April 27, 2021: JNJ Innovations is hosting a May 10 panel focusing on innovation in maternal health. The awardees of last fall’s Maternal Health QuickFire Challenge, which recognized innovation solutions to help reduce the U.S’ maternal mortality rate, have been invited to participate in the panel. COO Colby Holtshouse will be representing Alydia.
March 30, 2021: Merck announced its acquisition of Alydia Health for up to $240 million on behalf of Organon: Merck’s planned spin-off. Organon’s focused on safer childbirth - a major unmet need in maternal health - and acquisition of Alydia allows an increased number of moms to access to Alydia’s quick and effective device to control postpartum hemorrhaging.
March 8, 2021: Alydia Health was named one of Fierce Medtech’s 2020 Fierce 15: a list that include medical technologies whose “advancements all have the potential to deliver changes in care that will outlast this pandemic”. You can read Alydia’s unique feature here.
February 13, 2021: Northeast Georgia Medical Center is the first hospital in Georgia to use Alydia’s Jada System. As Holt Harrison, MD - an OB/GYN with Northeast Georgia Physicians Group - said of Jada, it is a “fast, definitive and physiologic solution that can dramatically change the experience of mothers who experience postpartum hemorrhage.”
February 1, 2021: In this article for OBG Management, Dr. Kelly Gibson and Dr. Michelle Kominiarek explain how Jada works, its treatment success rates, and its effectiveness compared to other PPH treatment options.
January 25, 2021: Visit Alydia virtually at the Society for Maternal-Fetal Medicine (SMFM) 2021 conference. Even if you don’t have a SMFM ticket, you can follow the link and click Alydia’s name to see a short demo of the Jada® System, access a brochure, and chat with a company representative.
December 30, 2020: Healio Primary Care included FDA 510(k) clearance for Alydia’s Jada® System as one of the its top women’s health stories for 2020. Others include OB/GYNs’ recommendations for a safe pregnancy during COVID-19, a potential shortage of OB/GYNs, and FDA approval for the Twirla contraceptive patch.
October 30, 2020: Kathryn Wine, VP of Clinical Operations at Alydia Health, was featured in this profile from her alma mater: Boston University’s School of Public Health. This feature covers her work with Alydia, the need for Alydia’s Jada® System, and the way Jada® works to control postpartum hemorrhage and “bring calm back to the hospital room".
October 20, 2020: The Postpartum Hemorrhage Treatment Device Market research report has been published. It forecasts the market until 2027, focusing on current trends, market growth drivers, different challenges, and industry leaders, one of which is Alydia.
October 14, 2020: Alydia is one of the winners of JNJ Innovation’s Maternal Health QuickFire Challenge, which aims to find ideas to improving pregnancy, birth, and postpartum care. Other 2020 winners include the National Birth Equity Collaborative, Pronto International, and Memora Health.
October 4, 2020: Cleveland Clinic Innovation named the Jada® System as a Top 10 medical innovation for 2021. Jada is a vacuum-induced uterine tamponade to stop postpartum hemorrhaging: a leading cause of maternal mortality for moms around the world.
September 16, 2020: Erica Rogers, President and CEO of Silk Road Medical and an Alydia board member, was among the winners of the 2020 Entrepreneur Of The Year® Award in Northern California. She and the other five winners are eligible for consideration for the Entrepreneur Of The Year 2020 National Awards.
September 9, 2020: Alydia Health announced that it has received FDA 510(k) clearance for its Jada® System: a device that controls and treats postpartum hemorrhage (PPH) and abnormal postpartum uterine bleeding. This press release also includes a link to the company’s pivotal PEARLE Study.
September 9, 2020: Alydia’s pivotal PEARLE study was published in Obstetrics & Gynecology (the Green Journal). This study demonstrates that the company’s Jada® System is safe, is highly effective, controls postpartum bleeding within a median of three minutes, and was successful in the treatment of 94% of the 107 trial participants. The article will also be available in print in the November issue.
September 3, 2020: From 1993 to 2014, maternal mortality rates have tripled in the U.S – and women in the U.S. experience more complications and higher mortality than any other developed nation. Alydia Health has developed a Jada® System to address one of those complications: postpartum hemorrhage. This interview with CEO Rob Binney talks about this new innovative solution to save moms’ lives.
July 30, 2020: Alydia Health raised $13.9 million in a Series C financing, which was led by AXA Investment Managers and included existing investors, such as the Global Health Investment Fund and Avestria Ventures. The company also announced two new leadership appointments: Rob Binney as CEO and Colby Holtshouse, prior VP of Marketing and acting CEO, as COO.
February 24, 2020: Alydia Health has appointed Dr. Edward Evantash as Chief Medical Officer. Dr. Evantash practiced as an OB-GYN for nearly 20 years, served as Division Chief of Obstetrics and Gynecology at Tufts Medical Center, and, most recently, was Medical Director and Vice President, Global Medical Affairs at Hologic.
February, 5, 2020: Alydia Health announced that the company has completed enrollment in the pivotal PEARLE IDE Study. This study investigates the safety and effectiveness of the Jada® System, Alydia’s proprietary and innovative technology used to control postpartum hemorrhage rapidly and effectively.
January 10, 2020: Erica Rogers, President and CEO of Silk Road Medical, joins Alydia Health’s Board of Directors as a strategic advisor. Most recently, Ms. Rogers led Silk Road Medical’s TransCarotid Artery Revascularization (TCAR) devices through FDA approval, commercial scale-up and IPO. She also serves as a director to Sight Sciences and an advisor to Venture Investors.
January 2, 2019: In this feature on Alydia, Palo Alto Online describes Alydia’s device - the Jada® System - and the current need for it. Currently, postpartum hemorrhaging causes about 35% according to the Centers for Disease Control and Prevention (CDC) while severe maternal morbidity has nearly tripled between 1993 and 2014 in the United States alone.
December 21, 2018: How does a car accident lead to a career in medical technologies? In this MedTech podcast, Anne Morrissey explains how her healthcare career started with a car accident and lead to Alydia.
September 28, 2018: In 2011, then 22-year-old Jessie Becker developed Alydia Health, then known as InPress Technologies, as part of a startup competition. Her idea really started gaining traction -first with fundraising and then with the first study - when Anne Morrissey joined the team as CEO.
September 28, 2018: Alydia Health announced a $10 million Series B financing round. The round was led by the Global Health Investment Fund and included participation from Astia Angels and Avestria.
Next page: AmplifiDx (a Fund I investment)